Halotestin or Trenbolone: What Is the Difference

Halotestin (fluoxymesterone) and trenbolone are often mentioned side by side as the "harshest" androgens, yet pharmacologically they are very different substances. One is an oral 17α-alkylated derivative of testosterone, once approved for human use; the other is a 19-nortestosterone steroid that has reached us mainly from veterinary medicine. The editorial team explains exactly what the difference between them is.

Two molecules from different "families"

Anabolic-androgenic steroids (AAS) are conventionally divided into groups by their parent molecule: derivatives of testosterone, derivatives of dihydrotestosterone (DHT), and derivatives of 19-nortestosterone (nandrolone). Halotestin belongs to the first group, trenbolone to the third. This classification alone explains many differences in how they behave in the body.

Fluoxymesterone was synthesized in the 1950s and was registered as an oral androgen under the trade name Halotestin. It was prescribed for male hypogonadism, delayed puberty, and as palliative therapy for some forms of breast cancer in women. Today, in most countries the drug has been withdrawn from circulation or is practically no longer used.

Trenbolone was developed in the 1960s. For a time, the ester trenbolone hexahydrobenzylcarbonate (Parabolan, France) was produced for humans, but this drug was discontinued long ago. The main legal use of trenbolone acetate is implants to stimulate weight gain in cattle. In other words, trenbolone has no modern human indications.

They share one thing: both substances are strong agonists of the androgen receptor, and both are included in section S1 "Anabolic agents" of the WADA Prohibited List. There the similarity ends, and below the editorial team examines the differences point by point.

Chemical structure and dosage form

Fluoxymesterone is testosterone with three modifications: a fluorine atom at position 9α, a hydroxyl group at position 11β, and a methyl group at position 17α. It is precisely the 17α-methylation that protects the molecule from rapid breakdown by the liver during first pass, which is why the drug is active when taken orally.

Trenbolone is 19-nortestosterone with two additional double bonds (at positions 9 and 11), that is, a steroid with three double bonds in the ring system. It is not 17α-alkylated, so it is of little use in oral form and is produced as esters for injection or as implants.

A different dosage form also means different pharmacokinetics. Oral fluoxymesterone acts for a few hours, whereas the duration of trenbolone's action is determined by the ester: acetate is released quickly, enanthate more slowly. For risk assessment, it also matters that trenbolone products on the illegal market are often crudely reprocessed veterinary products of unpredictable quality.

The stability of the molecules is worth mentioning separately. Trenbolone is sensitive to light, and its metabolites differ from those of most other steroids, which matters for anti-doping laboratories. Fluoxymesterone also has a recognizable metabolic "trace" because of the fluorine atom.

Mechanism of action: receptors and metabolism

Both substances act through the androgen receptor, but with different affinity. According to a review by Yarrow and colleagues (2010), trenbolone binds to the androgen receptor much more strongly than testosterone, and in animal experiments it shows a pronounced anabolic effect on muscle tissue. As for fluoxymesterone, its receptor affinity in laboratory tests is comparatively low, despite pronounced androgenic effects in the clinic.

A substantial difference lies in metabolism by enzymes. Trenbolone is not converted to estradiol by aromatase and is not a substrate of 5α-reductase the way testosterone is. At the same time, it has affinity for the progesterone receptor, so it is credited with progestogenic effects, in particular on the hypothalamic-pituitary axis.

Fluoxymesterone also practically does not aromatize, so classic estrogenic effects are not characteristic of it. Instead, the 17α-methyl group makes it a typical representative of oral steroids with a pronounced effect on the liver and lipid metabolism.

• In common:androgen receptor agonists, suppression of one's own production of LH and FSH, effect on lipids.
• Halotestin only:17α-alkylation, oral activity, hepatotoxicity characteristic of this class.
• Trenbolone only:19-nor structure, progestogenic activity, absence of modern human indications.

Both drugs suppress the hypothalamic-pituitary-gonadal axis. This means a decrease in one's own testosterone, reduced spermatogenesis, and a risk of prolonged hypogonadism after discontinuation, described in detail in a review by Rahnema and colleagues (2014).

Medical status and clinical data

For fluoxymesterone there are official FDA labels with indications, contraindications, and warnings. They describe, among other things, the risks of cholestatic hepatitis, peliosis hepatis, and liver tumors with long-term use of androgens, as well as virilization in women. Modern endocrinology guidelines for the treatment of hypogonadism do not recommend oral 17α-alkylated androgens.

For trenbolone the clinical base in humans is minimal: the main data were obtained in animal experiments and veterinary studies. Researchers considered trenbolone as a model of a tissue-selective androgen, but it never reached controlled clinical trials by modern standards.

From this follows an important practical conclusion: for trenbolone there are no reliable data on safety in humans, and everything circulating in the sports community is mostly anecdotal observation. For halotestin data do exist, but they concern medical doses decades ago and do not describe supraphysiological use.

Neither substance is used in modern sports medicine. Both are banned by WADA both in and out of competition, and detection of their metabolites is grounds for disqualification.

Risk profile: liver, heart, psyche

For halotestin the main specific risk is the liver. Like other 17α-alkylated steroids, it can cause cholestasis, elevated transaminases, and, with long-term use, peliosis hepatis and adenomas. The LiverTox library (NIH) classifies such injuries as typical for anabolic steroids.

For trenbolone cardiovascular and neuropsychiatric effects are discussed more often. Like other AAS in supraphysiological amounts, it lowers HDL, can raise blood pressure, and contribute to myocardial changes. An Endocrine Society review (Pope et al., 2014) describes, for AAS in general, an increased frequency of irritability, aggressiveness, and depression after withdrawal.

Both substances carry a high risk of virilization for women: coarsening of the voice, male-pattern hair growth, menstrual cycle disturbances. Some of these changes are irreversible.

Another factor is quality. Substances on the illegal market often do not match the stated composition, and injectable forms made in a makeshift way carry a risk of infectious complications.

Editorial conclusions

Halotestin and trenbolone differ in chemical family, dosage form, metabolism, and medical status. The first is an oral 17α-alkylated testosterone derivative with pronounced hepatotoxicity; the second is an injectable 19-nor steroid with progestogenic activity, created for animals.

What they have in common is strong suppression of one's own hormonal system, a negative effect on lipids, and a WADA ban. For trenbolone, moreover, there are practically no clinical data on safety in humans.

If you are interested in the topic of androgens, the editorial team advises starting with an understanding of how your own hormonal system works and with laboratory health monitoring, rather than with a comparison of the "strength" of drugs.

We also recommend reading our materials "Halotestin vs Trenbolone: what to choose and for whom," about the effect of oral steroids on the liver, and about the recovery of hormonal balance after AAS.

References

1. Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502–521.
2. Yarrow JF, McCoy SC, Borst SE. Tissue selectivity and potential clinical applications of trenbolone (17β-hydroxyestra-4,9,11-trien-3-one): a potent anabolic steroid with reduced androgenic and estrogenic activity. Steroids. 2010;75(6):377–389.
3. Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341–375.
4. Rahnema CD, Lipshultz LI, Crosnoe LE, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–1279.
5. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Androgenic Steroids. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases.
6. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
7. World Anti-Doping Agency. International Standard: Prohibited List. Montreal: WADA; 2025.